Skip to main content
. Author manuscript; available in PMC: 2019 Jun 17.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 14;16(10):2083–2093. doi: 10.1158/1535-7163.MCT-17-0089

Figure 4. Triple therapy with alisertib + ibrutinib + rituximab mitigates alisertib induced AASCs in DH/DE-DLBCL and induces apoptotic cell death through DNA damage.

Figure 4.

U2932 cells were treated with 50nM alisertib, 2.0μM ibrutinib, 10μg/ml cross-linked rituximab and their combination for 4 days. Flow cytometry data shows that with triple therapy (A) The aneuploid population is reduced (B) The senescent population is also reduced (C) Induces significant apoptosis and (D) DNA breaks evident by TUNEL assay.